§ PKAsia-Pacific
🇵🇰

Pakistan

Drug Regulatory Authority of Pakistan (DRAP)

GEBy GlobalReg EditorialLast verified 4/25/2026
Updated 6 days agomedium confidence
Export PDF
Lead approval timeline
180–365 days
180–365 days · Abridged / Reliance Registration (SRA-approved products)
Application fee
PKR 500K
PKR 500,000 · Same fee schedule as standard registration
English submissions
Accepted
English
eCTD
CTD only
See dossier notes
Local representative
Required
RP also required
Reliance pathway
Available
8 reference agencies
Last verified 4/25/2026 · by GlobalReg Editorial
What this means: A snapshot of who regulates medicines in this country, what languages they accept, and which international standards they recognise.
Country brief
Pakistan

Pakistan regulates therapeutic goods through the Drug Regulatory Authority of Pakistan (DRAP), a federal autonomous body established under the DRAP Act, 2012. DRAP administers registration of pharmaceutical, biological and medical device products under the Drugs Act, 1976 and subordinate rules (notably the Drugs (Licensing, Registering and Advertising) Rules, 1976). Statutory registration decisions are made by the Registration Board, supported by Divisions of Pharmaceutical Evaluation & Registration (PE&R) and Biological Drugs (BE&R). DRAP operates standard registration and abridged / reliance pathways for products approved by Stringent Regulatory Authorities (SRAs) and WHO-prequalified products. Pakistan applies statutory price control on registered medicines through the Drug Pricing Policy 2018 (and subsequent revisions), administered by DRAP's Division of Pharmacy Services / Pricing Committee. The market is large (>240 million population) but heavily generics-focused.

Verified 4/25/2026 · GlobalReg Editorial
Regulatory authority
DRAP
Operating language
English (and Urdu for labelling)
English submissions
Accepted
Submission languages
English
CTD format
Accepted
eCTD format
Not accepted

About the authority

DRAP is the federal regulator for therapeutic goods in Pakistan, established under the DRAP Act, 2012. It comprises divisions for Pharmaceutical Evaluation & Registration (PE&R), Biological Drugs Evaluation & Research (BE&R), Medical Devices, Quality Assurance & Lab Testing, Pharmacy Services (pricing), and Pharmacovigilance. The Registration Board approves product registrations on the recommendation of the relevant division. The Central Licensing Board licenses manufacturers; provincial authorities (e.g., Punjab Drug Control) handle distribution and retail.

International affiliations

WHOPIC/S applicantICDRA participant
Visit official website

Reliance & recognition

DRAP recognises Stringent Regulatory Authority (SRA) approvals and WHO Prequalification as the basis for abridged review. Submissions still require a complete CTD dossier and local administrative documentation, but assessment focuses on the SRA report and CMC/labelling consistency.

FDA (US)EMAMHRA (UK)Health CanadaTGA (Australia)PMDA (Japan)SwissmedicWHO Prequalification

Compare Pakistan side-by-side

Benchmark timelines, fees and pathway requirements against another market.

Other Asia-Pacific markets

Same structure. Same source-citation standard.